CLINICAL_TRIALS ClinicalTrials.gov record update

Iparomlimab and Tuvonralimab (QL1706) With Bevacizumab and RALOX Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma (HCC) With Vp3/4 Portain Vein Thrombosis : A Prospective, Multicenter, Phase II Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07327788
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:39.192346+00:00
Published At: 2026-01-13T00:00:00+00:00
Record Updated At: 2026-01-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hepatecellular Carcinoma", "RALOX-HAIC\uff08Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin", "Bevacizumab", "Type VP3/4 Portal Vein Tumor Thrombosis", "Iparomlimab and Tuvonralimab Injection", "QL1706"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-13"
protocolSection.identificationModule.nctId: "NCT07327788"
protocolSection.identificationModule.officialTitle: "Iparomlimab and Tuvonralimab (QL1706) With Bevacizumab and RALOX Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma (HCC) With Vp3/4 Portain Vein Thrombosis : A Prospective, Multicenter, Phase II Study"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.